Medtronic received information via literature regarding a comparison of the hemodynamic profiles between the trifecta and mosaic ultra bioprosthetic surgical valves.All data were collected from a single center between september 2012 and november 2014.The study population included 90 patients and was predominantly male with a mean age of 77 years.Of those, 38 were implanted with medtronic mosaic ultra valves in the aortic position.No serial numbers were provided.Among all patients, 2 deaths occurred due to: cerebral stroke (1) and lung infection with renal failure (1).The type of valve (trifecta or mosaic ultra) that was used to treat these 2 patients was not reported.Based on the available information, medtronic product was not directly associated with the deaths.Among all patients, adverse events included: reoperation due to endocarditis, myocardial infarction, post-operative atrial fibrillation, high transvalvular gradients, and patient-prosthesis mismatch.Based on the available information, medtronic product may have been associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|